

**VIVALIS enters NYSE Euronext indexes
SBF 250 and CAC Small 90**

Nantes (France) – December 1st, 2009 : VIVALIS (NYSE Euronext Paris: VLS), a biopharmaceutical company that provides the pharmaceutical industry with innovative cell-based solutions for the manufacture of vaccines and proteins and develops drugs to prevent and treat viral diseases, announces today that its stock will enter the CAC Small 90 and SBF 250 indexes.

The NYSE Euronext Scientific Board on Indexes, that met on November 26, 2009, has decided to include VIVALIS in the CAC Small 90 and SBF 250 indexes. This inclusion in these two reference indexes of the French stock market will be effective on Monday December 21st, 2009.

Franck Grimaud, C.E.O. and Majid Mehtali, C.S.O., co-managers of VIVALIS, declared: « *We are very happy of the integration of the VIVALIS stock in these two leading indexes of NYSE Euronext only two years after our IPO. This inclusion is also the result of the increased liquidity of our stock and will improve the visibility and recognition of VIVALIS in the investment community.* »

**Financial press release:
27 January 2010, after NYSE Euronext market closing: 2009 annual revenues**

About the EB66[®] line

The EB66[®] cell line, derived from duck embryonic stem cells, presents unique industrial and regulatory characteristics such as long-term genetic stability, immortality and cell growth to high cell densities in suspension in a serum-free medium (>20 millions cells/mL).

The BMF (Biologics Master File) for the registration of the EB66[®] cell line with the FDA (U.S. Food and Drug Administration) was filed on June 27, 2008.

The EB66[®] cell line is currently used or being tested by 75% of the major players in vaccines. VIVALIS has furthermore demonstrated that the EB66[®] cell line can be easily genetically modified, permitting the expression of recombinant proteins of potential interest. Moreover the glycosylation profile of monoclonal antibodies produced through EB66[®] cell lines is similar to the glycosylation profiles of human monoclonal antibodies with the added benefit of being distinguished by reduced fucose content. This latter characteristic is known to be associated with a higher level of antibody cytotoxic activity, particularly useful in the treatment of cancer cells.

About VIVALIS (www.vivalis.com)

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of viral diseases. VIVALIS' expertise and intellectual property are exploited in three main areas:

1. The development and manufacturing of vaccines. VIVALIS offers research and commercial licenses for its EB66® cell line, derived from duck stem cells, to pharmaceutical and biotechnology companies for the production of vaccines. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.
2. The development of production systems for recombinant proteins and monoclonal antibodies. VIVALIS licenses its EB66® cell line for the production of recombinant proteins to biotechnology and pharmaceutical companies. Vivalis receives upfront fees, milestone payments and royalties on its licensees' net sales.
3. The construction of a portfolio of proprietary products in the area of vaccines and anti-viral molecules (hepatitis C).

Based in Nantes (France), VIVALIS was founded in 1999 by the Grimaud group (1,450 employees), the second largest group worldwide in animal genetic selection. Part of the stem cell technology originated from INRA, CNRS, ENS research VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, CSL, Kaketsuken, Merial, Intervet, SAFIC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES bio-cluster.

VIVALIS

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's Next Biotech index



Contacts

VIVALIS

Franck Grimaud, CEO

Email: investors@vivalis.com

NewCap

Financial communications agency

Steve Grobet / Emmanuel Huynh

Tel.: +33 (0) 1 44 71 94 91

Email: vivalis@newcap.fr